journal article·2021-10

Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors

Ruxing Fu, Hongjun Li, Ruoxin Li, Kyle McGrath, Gianpietro Dotti, Zhen Gu

Advanced Functional Materials· Volume 31· Issue 44
Publisher page

Abstract

Abstract Chimeric antigen receptor (CAR) T cells exhibit promising results for cancer immunotherapy. However, the clinical success is still restricted to certain types of blood cancers, while in solid tumors the clinical activity is modest and potential toxicities remain a concern. There are various barriers that prevent CAR T cells from combating solid tumors. Therefore, distinct strategies have been explored to augment CAR T cell proliferative capacity, persistence, and effector function. Altering the tumor microenvironment, and in particular its physiochemical properties and immunosuppressive milieu, is of great significance to facilitate CAR T cell therapy. In this article, emerging strategies implemented to overcome the barriers of CAR T cell therapy in solid tumors are reviewed. Enhancing infiltration, activation, and persistence of CAR T cells has been addressed in several preclinical models. The future development of this field to promote innovation and clinical translation is also discussed.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: CAR-T cell therapy research · Nanowire Synthesis and Applications · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering University of California Los Angeles CA 90095 USA

California NanoSystems Institute University of California Los Angeles CA 90095 USA

Department of Materials Science and Engineering University of California Los Angeles CA 90095 USA

College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P. R. China

Department of Chemical and Biomolecular Engineering University of California Los Angeles CA 90095 USA

Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill NC 27599 USA

Department of Microbiology and Immunology University of North Carolina Chapel Hill NC 27599 USA

Jonsson Comprehensive Cancer Center University of California Los Angeles CA 90095 USA

Center for Minimally Invasive Therapeutics University of California Los Angeles CA 90095 USA

Funding

National Institutes of Health · University of California, Los Angeles

References (100+)

Show source-provided references
1. 10.1126/science.aar671110.1126/science.aar6711 ↗
2. 10.1038/nrclinonc.2016.3610.1038/nrclinonc.2016.36 ↗
3. 10.1038/nrd459710.1038/nrd4597 ↗
4. 10.1038/s41551-018-0235-910.1038/s41551-018-0235-9 ↗
5. 10.1038/s41591-019-0564-610.1038/s41591-019-0564-6 ↗
6. 10.1038/mto.2016.1410.1038/mto.2016.14 ↗
7. 10.1038/s41416-018-0325-110.1038/s41416-018-0325-1 ↗
8. 10.1016/j.omtm.2016.12.00610.1016/j.omtm.2016.12.006 ↗
9. 10.1056/NEJMoa110384910.1056/NEJMoa1103849 ↗
10. 10.1056/NEJMoa170856610.1056/NEJMoa1708566 ↗
11. 10.1056/NEJMoa170991910.1056/NEJMoa1709919 ↗
12. d)U.S. Food & Drug Administration FDA approves CAR‐T cell therapy to treat adults with certain types of large B‐cell lymphoma https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐car‐t‐cell‐therapy‐treat‐adults‐certain‐types‐large‐b‐cell‐lymphoma(accessed: June2020).
13. 10.1146/annurev-med-062315-12024510.1146/annurev-med-062315-120245 ↗
14. 10.3389/fimmu.2018.0259310.3389/fimmu.2018.02593 ↗
15. 10.1038/s41571-019-0297-y10.1038/s41571-019-0297-y ↗
16. 10.1038/s41571-019-0184-610.1038/s41571-019-0184-6 ↗
17. 10.1038/icb.2016.12810.1038/icb.2016.128 ↗
18. 10.1126/science.aaa620410.1126/science.aaa6204 ↗
19. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
20. 10.1182/blood-2009-03-20965010.1182/blood-2009-03-209650 ↗
21. 10.1097/CJI.0b013e3181ee667510.1097/CJI.0b013e3181ee6675 ↗
22. 10.1158/1078-0432.CCR-11-035110.1158/1078-0432.CCR-11-0351 ↗
23. 10.1038/nbt.310410.1038/nbt.3104 ↗
24. 10.1038/s41551-019-0486-010.1038/s41551-019-0486-0 ↗
25. 10.1002/adma.20190019210.1002/adma.201900192 ↗
26. 10.1038/nm.383310.1038/nm.3833 ↗
27. 10.1158/2326-6066.CIR-13-002710.1158/2326-6066.CIR-13-0027 ↗
28. 10.1073/pnas.181714711610.1073/pnas.1817147116 ↗
29. 10.1038/nbt.408610.1038/nbt.4086 ↗
30. 10.1016/j.celrep.2017.11.06310.1016/j.celrep.2017.11.063 ↗
31. 10.1016/j.celrep.2017.09.00210.1016/j.celrep.2017.09.002 ↗
32. 10.1158/1078-0432.CCR-11-305010.1158/1078-0432.CCR-11-3050 ↗
33. 10.1038/s41587-019-0398-210.1038/s41587-019-0398-2 ↗
34. 10.1038/natrevmats.2016.7510.1038/natrevmats.2016.75 ↗
35. 10.1172/JCI8341610.1172/JCI83416 ↗
36. 10.1016/j.cell.2018.03.03810.1016/j.cell.2018.03.038 ↗
37. 10.1038/s41587-019-0192-110.1038/s41587-019-0192-1 ↗
38. 10.1172/JCI8762410.1172/JCI87624 ↗
39. 10.1158/1078-0432.CCR-17-086710.1158/1078-0432.CCR-17-0867 ↗
40. 10.1038/nbt.419510.1038/nbt.4195 ↗
41. 10.1126/science.aav869210.1126/science.aav8692 ↗
42. 10.1158/1078-0432.CCR-12-144910.1158/1078-0432.CCR-12-1449 ↗
43. 10.1158/0008-5472.CAN-11-389010.1158/0008-5472.CAN-11-3890 ↗
44. 10.1158/1078-0432.CCR-19-183510.1158/1078-0432.CCR-19-1835 ↗
45. 10.1158/2326-6066.CIR-15-026310.1158/2326-6066.CIR-15-0263 ↗
46. 10.1038/nri.2017.4910.1038/nri.2017.49 ↗
47. 10.1158/2326-6066.CIR-13-017010.1158/2326-6066.CIR-13-0170 ↗
48. 10.1056/NEJMoa161049710.1056/NEJMoa1610497 ↗
49. 10.1158/1078-0432.CCR-14-142110.1158/1078-0432.CCR-14-1421 ↗
50. 10.1158/2326-6066.CIR-17-018910.1158/2326-6066.CIR-17-0189 ↗
51. 10.3390/cancers907009210.3390/cancers9070092 ↗
52. 10.1056/NEJMoa05142410.1056/NEJMoa051424 ↗
53. 10.1038/nm109310.1038/nm1093 ↗
54. 10.3389/fonc.2019.0032210.3389/fonc.2019.00322 ↗
55. 10.1158/2326-6066.CIR-16-001110.1158/2326-6066.CIR-16-0011 ↗
56. 10.1038/nrc158610.1038/nrc1586 ↗
57. 10.1084/jem.2013011010.1084/jem.20130110 ↗
58. 10.1021/ja201017510.1021/ja2010175 ↗
59. 10.1021/ja057254a10.1021/ja057254a ↗
60. 10.1126/sciimmunol.aan569210.1126/sciimmunol.aan5692 ↗
61. 10.1002/advs.20190316410.1002/advs.201903164 ↗
62. 10.1111/imr.1212510.1111/imr.12125 ↗
63. 10.1038/ni151310.1038/ni1513 ↗
64. 10.3389/fcell.2019.0021210.3389/fcell.2019.00212 ↗
65. 10.2174/09298671079317634810.2174/092986710793176348 ↗
66. 10.1182/blood-2011-12-40004410.1182/blood-2011-12-400044 ↗
67. 10.1056/NEJMoa110615210.1056/NEJMoa1106152 ↗
68. 10.1016/j.it.2013.07.00410.1016/j.it.2013.07.004 ↗
69. 10.1073/pnas.161054411310.1073/pnas.1610544113 ↗
70. Chen Y. · J. Immunol. · 2017 · 198 · 204.2310.4049/jimmunol.198.Supp.204.23 ↗
71. Li X. · Leukemia · 2020
72. 10.1158/2326-6066.CIR-16-037610.1158/2326-6066.CIR-16-0376 ↗
73. 10.1016/S0140-6736(14)61403-310.1016/S0140-6736(14)61403-3 ↗
74. 10.1038/s41375-019-0488-710.1038/s41375-019-0488-7 ↗
75. 10.1186/s13045-018-0646-910.1186/s13045-018-0646-9 ↗
76. 10.1021/jacs.5b0010610.1021/jacs.5b00106 ↗
77. 10.1073/pnas.152419311310.1073/pnas.1524193113 ↗
78. 10.1158/0008-5472.CAN-18-183410.1158/0008-5472.CAN-18-1834 ↗
79. 10.1038/mt.2014.15610.1038/mt.2014.156 ↗
80. 10.1158/2326-6066.CIR-17-031410.1158/2326-6066.CIR-17-0314 ↗
81. 10.1200/JCO.2014.59.435810.1200/JCO.2014.59.4358 ↗
82. 10.1158/1078-0432.CCR-13-262710.1158/1078-0432.CCR-13-2627 ↗
83. 10.1056/NEJMra151429610.1056/NEJMra1514296 ↗
84. 10.3390/ijms1902034010.3390/ijms19020340 ↗
85. 10.1182/blood-2018-99-11257210.1182/blood-2018-99-112572 ↗
86. 10.1200/JCO.2019.37.15_suppl.251110.1200/JCO.2019.37.15_suppl.2511 ↗
87. 10.1172/JCI8309210.1172/JCI83092 ↗
88. 10.1158/0008-5472.CAN-15-252410.1158/0008-5472.CAN-15-2524 ↗
89. 10.1038/s41598-017-00462-810.1038/s41598-017-00462-8 ↗
90. 10.1038/s41573-019-0051-210.1038/s41573-019-0051-2 ↗
91. 10.1007/s40259-017-0247-010.1007/s40259-017-0247-0 ↗
92. 10.3389/fonc.2018.0045310.3389/fonc.2018.00453 ↗
93. 10.3390/cells805047210.3390/cells8050472 ↗
94. 10.1038/nnano.2017.5710.1038/nnano.2017.57 ↗
95. 10.1038/nbt.404710.1038/nbt.4047 ↗
96. 10.1002/adhm.20200027510.1002/adhm.202000275 ↗
97. 10.1021/acs.nanolett.9b0424610.1021/acs.nanolett.9b04246 ↗
98. 10.1021/mp500656v10.1021/mp500656v ↗
99. 10.1007/s41061-017-0128-510.1007/s41061-017-0128-5 ↗
100. 10.1126/science.276.5319.171910.1126/science.276.5319.1719 ↗